|
Generic Name (Abbreviation)/ Trade Name
|
Formulation
|
Dosing Recommendations
(For dosage adjustment in hepatic insufficiency, see Appendix B, Table 7.)
|
Serum Half-Life
|
Elimination
|
Adverse Events
(Also see Table 13)
|
Maraviroc
(MVC)/
Selzentry |
150 and 300 mg tablets |
150 mg BID when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except TPV/r)
300 mg BID when given with NRTIs, T20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers
600 mg BID when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)
Take without regard to meals
|
14-18 hours |
CYP3A4 substrate |
- Abdominal pain
- Cough
- Dizziness
- Musculoskeletal symptoms
- Pyrexia
- Rash
- Upper respiratory tract infections
- Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions
- Orthostatic hypotension, especially in patients with severe renal insufficiency
|